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The purpose of the research was exploration of the impact of the conventional 
treatment in combination with simvastatin and iodine-containing pumpkin oil 
“Fortuna vita” on the values of lipid metabolism in cardiac ischemia patients 
residing in the setting of iodine deficit. The patients were divided into 2 groups: 
group 1– patients underwent conventional treatment with application of simvastatin 
of 20mg/day during the whole course of observation; group 2 – same treatment in 
combination with iodine-containing pumpkin oil “Fortuna vita” of 10ml/day, which 
contains 200μg of organically combined iodine form. The level of total cholesterol, 
triglycerides, high-density lipoprotein cholesterol (HDL cholesterol) and low-
density lipoprotein cholesterol (LDL cholesterol) in serum, and aspartate 
aminotransferase and alanine aminotrasferase in patients before treatment, after 10 
days, and after 1 month of treatment was measured. It was determined, that 
simvastatin is an effective and safe cholesterol-reducing preparation for cardiac 
ischemia patients which results in reduction of cholesterol level by 18% and LDL by 
23% in one month. A combination of simvastatin and iodine-containing pumpkin oil 
appears more effective, probably because of potentiation of their effects, which also 
facilitate growth of antiatherogenic HDL and consequently decrease the 
atherogenicity coefficient. The general clinical state of both groups improved as a 
result of the treatment, though more so for the patients treated in combination with 
iodine-containing pumpkin oil. We are inclined to explain this fact by normalization 
of iodine-thyroid status, and consequently, of the general metabolism of the patients 
in the setting of ecologic iodine deficit because of iodine-containing fatty acids. 
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Introduction 
 
Cardiovascular pathology remains the main cause of illnesses and mortality 
in the world. So, according to WHO nearly 17mln people die from cardiovascular 
diseases every year. In the structure of mortality caused by cardiovascular 
pathology cardiac ischemia keeps more than 60% (ex. Kovalenko, 2007). At the 
same time, the results of multiple experimental, epidemiologic and clinical 
researches conducted recently leave no room for doubts as to the influence of 
lipidosis on the development and complications of atherosclerosis. Firstly it relates 
to illnesses and mortality caused by cardiac ischemia. More than 15% of adult 
population in Ukraine suffer from cardiac ischemia. Dislipidemy, in particular 
increased level of total cholesterol is registered among 48.5% of males in the age 
of 40-60 and 56.3% of women, while prevalence and mortality from cardiac 
ischemia is one of the highest in Europe (ex. Lutaj et al., 2007). Therefore the 
system of cardiovascular preexposure and postexposure prophylaxis measures 
directed at correction of hypercholesterolemia as the main aterosclerosis and 
cardiac ischemia risk factor becomes especially important (ex. Lutaj et al., 2007).  
Hypercholesterolemia is regarded as the main risk factor of atherosclerosis 
development and complications. In particular, hyperlipoidemia lowers nitric oxide 
bioavailability upsetting the flow-dependent artery dilation. According to modern 
views endothelium dysfunction is the main factor facilitating increased penetration 
of low-density lipoproteins (LDL) to the intima of coronary arteries, which triggers 
a series of normal homeostasis dysfunctions. Hence, endothelium dysfunction is 
the initial stage of changes leading to formation of atherosclerotic plaque. 
Prevention of atherosclerosis risk factors is essential for decreasing the risks of 
cardiovascular diseases. Impact on the high level cholesterol and low-density 
lipoproteins must be regarded as the most substantiated and effective method of 
preexposure and postexposure prophylaxis among various approaches to 
atherosclerotic plaque stabilization (ex. Kovalenko, 2007). This means the 
necessity of prescribing cholesterol-reducing therapy and reaching target level of 
cholesterol content in blood.  
Decreasing the high level of total cholesterol and its fraction LDL 
cholesterol is the primary task of hypolipidemic therapy, since there are cogent 
proofs as to close correlation between these indexes and development and 
progressing of atherosclerosis and its complications (ex. Metelitsa, 2002; Gotto, 
2003). Currently the indexes of total cholesterol <5.0mmole/l and LDL cholesterol 
< 3mmole/l are considered as normal at the population level. For patients with 
present cardiovascular diseases, primarily cardiac ischemia, and other 
atherosclerosis manifestations the target levels of these indexes are set as 
<4.5mmole/l for total cholesterol, and <2.5mmole/l for LDL cholesterol – 
achieving these in the process of treatment is reliably followed by reduction of 
cardiovascular complications and improvement of prognosis. 
Statins (HMG-CoA reductase inhibitors) are the main pharmacologic means 
of dislipidemy prevention these days. They both decrease the level of total   577
cholesterol and LDL cholesterol, and have a positive effect on LDL subfractions 
reducing the share of the most atherogenic ones – small dense particles and 
triglycerides (ex. Gotto et al., 2003). It must be noted, that hypertriglyceridemia 
and low HDL cholesterol level are also the risk factors of atherosclerosis and 
cardiac ischemia, which must be taken in consideration when selecting the therapy. 
Cardiovascular risk is known to increase in case of triglyceride growing > 
1.7mmole/l and HDL cholesterol level dropping < 1.0mmole/l for men and 
<1.2mmole/l for women.  
Now appropriateness of statins application for preexposure prophylaxis of 
arterial hypertension patients is beyond any doubt. Meta-analysis of multicenter 
researches conducted during the recent year demonstrates possibility to decrease 
the general death rate by 9 to 30% and stroke development risk by 19 to 31% in 
case of applying statins therapy (ex. Sirenko et al., 2008; Duovne et al., 2000; 
.Moron et al., 2000; Cholesterol treatment, 2005). 
Lipid-reducing effect of statins is connected with reverse blocking of HMG-
CoA reductase enzyme which enables intracellular cholesterol synthesis. The total 
cholesterol level in plasma is decreased same as cholesterol fractions, in particular 
LDL by 25-40% on average, and lipoproteins with high triglyceride content. 
Therapy with statins is characterized by moderate growth of HDL cholesterol (by 
5-15%) and decrease of triglyceride level (by 15-30%). Statins lower the risk of 
atherosclerotic cardiovascular complications by 30% on average (ex. Gotto, 2003). 
Wide-range researches of taking simvastatin during 5.5 years demonstrated 
its effectiveness as to prevention of the main vascular complications (myocardial 
infarction, stroke, need of revasculization). As a result of this the integrated index 
of cardiovascular complications rate dropped by 24%. At the same time positive 
results were observed in various subgroups: men and women; patients of various 
age; and which is extremely important, regardless of the initial rates of total 
cholesterol and LDL cholesterol. During taking simvastatin the ischemic risk 
decreased by 27% (ex. Aronov, 2001), other authors state even higher percentage – 
30-40% (ex. Pyorala et al., 2004). 
Considering the results of the wide-scale researches, prescription of statins is 
now recommended for postexposure prophylaxis to all patients with diagnosis of 
cardiac ischemia and high risk of cardiovascular complications regardless of the 
age, sex, and initial cholesterol level (ex. Lutaj et al.,2007). 
Besides, the effect of omega-3 polyunsaturated fatty acids on lipid 
metabolism is known to exhibit decreased triglyceride and apolipoprotein B 
synthesis in liver, LDL excretion from bloodstream. Indirect decreasing of LDL 
and increasing of HDL is also achieved due to more intense excretion of bile acids. 
Positive effects of omega-3 polyunsaturated fatty acids were confirmed by 
randomized placebo controlled researches of cardiologic patients. So, it was 
demonstrated that cardiac mortality decreased by 50% and nonfatal myocardial 
infarction lowered by 48% among the patients after myocardial infarction who 
additionally took polyunsaturated fatty acids. It was additionally determined, that 
taking omega-3 polyunsaturated fatty acids with food leads to growth of   578
antiatherogenic HDL in serum and is accompanied by significant reduction of all 
atherogenic fractions. Multi-aspect effects of omega-3 polyunsaturated fatty acids 
on cellular membranes were discovered: due to their integration into the structure 
the biophysical and physiologic properties of cellular membranes change, they 
become less viscous and more permeable, the structure and functions of ion 
channels change. Omega-3 polyansaturated fatty acids also slow down free radicals 
creation and lipid pereoxidation (ex. Rudenko, 2008). Therefore, considering the 
above data application of omega-3 polyunsaturated fatty acids is reasonable for 
treatment of dislipoproteinemia patients, particularly during treatment with statins 
which may exhibit hepatotoxic effect. 
Our previous researches demonstrated the effect of iodine-containing fatty 
acids as effective means for iodine deficit prevention, correction of thyroid gland 
function, which has antiatherogenic properties, increases resistibility of the 
organism to the impact of xenobiotics and other unfavorable environmental factors, 
increases immunologic reactivity of the organism, has an anti-oxidant effect (ex. 
Turianica et al., 2002, 2002 а). 
The purpose of the research was exploration of the impact of the 
conventional treatment in combination with simvastatin and iodine-containing 
pumpkin oil “Fortuna vita” on the values of lipid metabolism in cardiac ischemia 
patients residing in the setting of iodine deficit. 
 
Materials and Methods 
 
The research was conducted according to the clinical research requirements 
of Ukraine. It included 25 patients with the following diagnosis: cardiac ischemia, 
exertional angina of functional classes II-III, atherosclerotic cardiosclerosis, 
essential hypertension II-III, cardiac failure II A, who were subject to inpatient 
treatment at the general cardiologic department of the regional cardiologic 
dispensary (Uzhgorod, Zakarpattya region, Ukraine) and who reside in 
biogeochemical region with ecologically conditioned iodine deficit (ex. Turianica, 
et al., 2007). The average age of the patients was 56.3±5.8 years.  
The patients were divided into 2 groups: group 1 – patients were 
conventionally treated according to the recommendations of the Ministry of 
Healthcare of Ukraine with application of simvastatin of 20mg/day during the 
course of observation; group 2 – same treatment in combination with iodine-
containing pumpkin oil “Fortuna vita” of 10ml/day, which contains 20mcg of 
organically combined iodine form. 
According to the research minutes biochemical analysis was performed 
before treatment, after 10 days of treatment and 1 month after the beginning of 
treatment. 
The level of total cholesterol, triglycerides, high-density lipoprotein 
cholesterol (HDL cholesterol) and low-density lipoprotein cholesterol (LDL 
cholesterol) in serum, and aspartate aminotransferase and alanine aminotransferase   579
was measured with test-kits (PLIVA-Lachema a.s., Czech Republic). 
Atherogenicity coefficient was estimated by the formula: (cholesterol – 
HDL)/HDL.  
Statistical processing was carried out after a computer database was formed 
in Microsoft Exel by means of personal computer with calculation of Student’s t-
test and means comparison. 
 
Result and Discussion 
 
It should be noted that all patients tolerated simvastatin treatment 
satisfactorily.  
Our research determined that after 10 days of conventional treatment with 
application of simvastatin the patients showed no significant change in lipid blood 
spectrum, however the levels of alanine aminotransferase and aspartate 
aminotransferase increased significantly (table 1). After one month of treatment of 
these patients the cholesterol level decreased significantly by 18% as compared to 
the values at the beginning of the observation, and the content of the most 
atherogenic fraction of LDL decreased by 23%, there was also a tendency of 
triglyceride level decrease (Р>0.05). It should be noted however, that while HDL 
level did not change significantly, there was a descending tendency (Р>0.3). 
Because of the low level of HDL cholesterol the atherogenicity coefficient did not 
change either and remained higher than normal (normal is <3).  We may not stress 
that monitoring of enzymes (alanine aminotransferase, aspartate aminotransferase) 
activity indicated their undesirable significant increase both compared to control 
and in the observation dynamics, though it did not exceed the safety level (ex. 
Armitage, 2007). Hence, treatment with simvastatin may be considered as safe and 
quite effective. Further observation of the patients will allow to obtain more distant 
results of treatment. 
Table 1 
Lipid metabolism indices of cardiac ischemia patients in the course of conventional 
treatment 
Indices Before 
treatment 
n=10 
After 10 days 
of treatment 
n=10 
After 1 month 
of treatment 
n=10 
Cholesterol  (mmole/l)  4.8±0.19 4.5±0.28 3.99±0.31  * 
HDL  (mmole/l)  0.95±0.08 0.89±0.09 0.83±0.07 
LDL  (mmole/l)  3.52±0.26 3.19±0.31 2.56±0.29  * 
Triglyceride  (mmole/l)  1.28±0.13 1.15±0.12 0.98±0.11 
Atherogenicity  coefficient  4.81±0.75 4.87±0.79 4.26±0.71 
Alanine aminotransferase 
(mmole/l) 
0.60±0.06  0.77±0.04 *  1.17±0.09 * ** 
Aspartate aminotransferase 
(mmole/l) 
0.58±0.04  0.74±0.03 *  1.14±0.09 * ** 
* and ** – reliability indicators compared to control and previous group respectively    580
It is important to note, that a combination of conventional treatment of 
patients by simvastatin and iodine-containing pumpkin oil as soon as after 10 days 
of treatment results in reliable 15% reduction of cholesterol, reduction tendency for 
atherogenic LDL (P > 0.05), and growth tendency for antiatherogenic HDL 
(P>0.05), which probably leads to decrease of atherogenicity coefficient, though 
not reaching the normal value. The levels of blood enzymes and triglycerides 
remain without change. After 1 month of the abovementioned complex treatment 
observed are reliable 19% decrease of cholesterol level, 27% decrease of LDL, 
38% drop of atherogenicity coefficient, and 20% increase of HDL. This is a very 
positive factor since as it is known a 1% decrease of LDL cholesterol decreases the 
cardiovascular risk by 1%, while a 1% increase of HDL lowers this risk by 3%. 
Furthermore, it is important that serum transaminase does not change significantly, 
and even have a tendency to decrease. We tend to explain these revealed additional 
positive effects by iodine-containing polyunsaturated fatty acids (including omega-
3) which are contained in iodine-containing pumpkin oil, since taking of such 
polyunsaturated fatty acids is know to decrease all atherogenic lipoprotein fractions 
and increase antiatherogenic ones (ex. Rudenko, 2008). On the other hand presence 
of iodine-containing fatty acids in pumpkin oil contributes to compensatory inflow 
of physiologic iodine doses to the organism, and, consequently, to normalization of 
thyroid regulation of substance and energy metabolism – proteins, amino acids, 
carbohydrates, lipids, cholesterol, water-salt metabolism, i.e. leveling of iodine 
deficit consequences (ex. Turianica et al., 2007).  Furthermore, omega-3 
polyunsaturated fatty acids have anti-oxidant properties which probably contribute 
to stabilization of hepatocyte membranes, and decreasing the hepatoxic effect of 
statins. 
At the same time triglyceride level did not decrease significantly which may 
be the consequence of oil intake. 
Table 2 
Lipid metabolism indices of cardiac ischemia patients in the course of conventional 
treatment combined with iodine-containing pumpkin oil 
Indices Before 
treatment 
n=15 
After 10 days 
of treatment  
n=15 
After 1 month 
of treatment 
n=15 
Cholesterol (mmole/l)  5.15±0.36  4.39±0.39 *  4.19±0.27 * 
HDL (mmole/l)  0.74± 0.05  0.87±0.06  0.93±0.10 * 
LDL  (mmole/l)  3.84±0.37 3.18±0.40 2.81±0.24  * 
Triglyceride (mmole/l)  2.16±0.30  1.8+0.30  1.75±0.41 
Atherogenicity coefficient  5.80±0.50  4.08±0.35 *  3.57±0.37 * 
Alanine aminotransferase 
(mmole/l) 
0.82±0.08 0.72±0.10 0.63±0.07   
Aspartate aminotransferase 
(mmole/l) 
0.70±0.08 0.69±0.08 0.60±0.05 
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Thus, simvastatin is an effective and safe cholesterol decreasing preparation 
for cardiac ischemia patients which as soon as after 1 month of application results 
in 18% decrease of cholesterol level, and 23% decrease of LDL.  
Combination of simvastatin and iodine-containing pumpkin oil appears more 
effective, probably because of potentiation of their effects, which lead to 
significant 19% decrease of cholesterol, 27% decrease of LDL, 38% drop of 
atherogenicity coefficient, and, which is particularly important, 20% increase of 
antiatherogenic HDL which are much more difficult for correction than atherogenic 
LDL, and, consequently, to decreased atherogenicity coefficient. At the same time 
it is also important, that during consumption of iodine-containing pumpkin oil the 
level of serum transaminase did not change significantly, unlike their growth in the 
first group of patients, which indicates its hepatoprotection effect and lessened side 
effect of simvastatin. 
In both groups of patients the treatment resulted in improved general clinical 
state, the number and duration of anginous strokes decreased, the need of 
nitropreparations decreased, physical stress tolerance increased, positive ECG 
dynamics was observed as decreased number of ST segment depressions, which 
was more so for patients undergoing treatment combined with iodine-containing 
pumpkin oil. This fact we tend to explain by normalization of iodine-thyroid status, 
and, consequently, the general metabolism of patients residing in ecological iodine 
deficit conditions, because of iodine-containing fatty acids (ex. Turianica et al., 
2007). 
Conclusions 
 
Simvastatin is an effective and safe cholesterol decreasing preparation for 
cardiac ischemia patients which as soon as after 1 month of application results in 
18% decrease of cholesterol level, and 23% decrease of LDL.  
Combination of simvastatin and iodine-containing pumpkin oil appears more 
effective, probably because of potentiation of their effects, which lead to 
significant 19% decrease of cholesterol, 27% decrease of LDL, 38% drop of 
atherogenicity coefficient, and, which is particularly important, 20% increase of 
antiatherogenic HDL. At the same time it is also important, that during 
consumption of iodine-containing pumpkin oil the level of serum transaminase did 
not change significantly, unlike their growth in the first group of patients, which 
indicates its hepatoprotection effect and lessened side effect of simvastatin. 
In both groups of patients the treatment resulted in improved general clinical 
state, which was more so for patients undergoing treatment combined with iodine-
containing pumpkin oil, probably because of normalization of iodine-thyroid 
status, and, consequently, the general metabolism of patients residing in ecological 
iodine deficit conditions, owing to iodine-containing fatty acids, in particular 
omega-3.  
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